<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404361</url>
  </required_header>
  <id_info>
    <org_study_id>PAC319</org_study_id>
    <nct_id>NCT04404361</nct_id>
  </id_info>
  <brief_title>PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate&#xD;
      the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or&#xD;
      without cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate&#xD;
      the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or&#xD;
      without cancer. Severe COVID-19 is defined as confirmed disease in patients who are&#xD;
      hospitalized with hypoxia (blood oxygen saturation [SpO2] ≤93% on room air at sea level),&#xD;
      respiratory rate &gt;30, arterial oxygen partial pressure [PaO2]/ fraction of inspired oxygen&#xD;
      [FiO2] &lt;300, or lung infiltrates &gt;50% but do not require IMV.&#xD;
&#xD;
      Patients will be randomized 1:1 to receive pacritinib (400 mg once daily [QD] on Day 1, then&#xD;
      200 mg twice daily [BID] from Day 2 to Day 14) + SOC or placebo + SOC.&#xD;
&#xD;
      Assigned treatment will continue for up to Day 14 or until the patient experiences&#xD;
      intolerable adverse events (AEs), withdraws consent, or initiates another investigational&#xD;
      therapy or until the study is terminated. Assigned therapy may be given for an additional 7&#xD;
      days (for a total of 21 days) with the approval of the Medical Monitor if, in the opinion of&#xD;
      the investigator, the patient's clinical signs and symptoms are improving and the potential&#xD;
      benefit outweighs the potential risk.In the event of hospital discharge, patients will&#xD;
      complete treatment with the assigned therapy as an outpatient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization</measure>
    <time_frame>28 days</time_frame>
    <description>The proportion is calculated as the number of patients who progress divided by the total number of patients in the ITT population.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>COVID19</condition>
  <condition>COVID-19</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Pacritinib and SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>100 mg capsules</description>
    <arm_group_label>Pacritinib and SOC</arm_group_label>
    <other_name>SB1518</other_name>
    <other_name>Oral Jak Inhibitor</other_name>
    <other_name>Oral Irak inhibitor</other_name>
    <other_name>Oral Csf1 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matching pacritinib 100 mg capsules</description>
    <arm_group_label>Placebo and SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized or will be hospitalized prior to randomization for the treatment of&#xD;
             severe COVID-19 with SARS-CoV-2 infection confirmed by either a) a positive reverse&#xD;
             transcriptase polymerase chain reaction (RT PCR) or b) an antigen-based test from any&#xD;
             respiratory, nasopharyngeal, saliva, blood, or stool specimen at Screening or&#xD;
             documented within 1 week prior to the start of Screening (Severe COVID-19 is defined&#xD;
             as confirmed disease in patients who are hospitalized with hypoxia [SpO2 ≤93% on room&#xD;
             air], respiratory rate &gt;30, PaO2/FiO2 &lt;300, but do not require IMV).&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Platelet count ≥ 50,000/µL&#xD;
&#xD;
          4. If fertile, willing to use effective birth control methods during the study&#xD;
&#xD;
          5. Provision of informed consent within 96 hours after hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, progression to death is imminent and inevitable&#xD;
             within the next 24 hours, irrespective of the provision of treatments&#xD;
&#xD;
          2. Currently intubated or intubated between screening and randomization&#xD;
&#xD;
          3. Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides&#xD;
             COVID 19)&#xD;
&#xD;
          4. Prior allogenic hematopoietic stem cell transplantation&#xD;
&#xD;
          5. Active lung cancer or history of lung cancer within the past 12 months&#xD;
&#xD;
          6. Any active grade 2 or higher hemorrhage&#xD;
&#xD;
          7. Any active gastrointestinal or metabolic condition that could interfere with&#xD;
             absorption of oral medication&#xD;
&#xD;
          8. Uncontrolled intercurrent illness that, in the judgment of the treating physician,&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          9. Known seropositivity for human immunodeficiency virus with cluster of differentiation&#xD;
             4 (CD4) count &lt; 200/mm3 within 3 months prior to randomization&#xD;
&#xD;
         10. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination&#xD;
&#xD;
         11. Concurrent enrollment in another interventional trial (investigational COVID-19&#xD;
             antiviral studies are permitted)&#xD;
&#xD;
         12. Serum creatinine &gt; 2.5 mg/dL&#xD;
&#xD;
         13. Total bilirubin &gt; 4× the upper limit of normal&#xD;
&#xD;
         14. QT corrected by the Fridericia method (QTcF) prolongation &gt; 480 msec&#xD;
&#xD;
         15. Known history of New York Heart Association Class II, III, or IV congestive heart&#xD;
             failure prior to hospital admission&#xD;
&#xD;
         16. Known allergic reaction to any Janus kinase 2 (JAK2) inhibitor&#xD;
&#xD;
         17. Exposure to any JAK2 inhibitor within 28 days&#xD;
&#xD;
         18. Currently receiving a strong CYP3A4 inhibitor or strong P450 inducer (Appendix 1 and&#xD;
             Appendix 2, respectively) and unable to stop the medication prior to the first dose of&#xD;
             study drug and throughout the duration of study drug administration&#xD;
&#xD;
         19. Treatment with cytoreductive chemotherapy administered within 14 days prior to&#xD;
             randomization&#xD;
&#xD;
         20. Administration of an IL 1 or IL 6 blocking immunomodulatory agent (such as&#xD;
             tocilizumab, canakinumab, sarilumab, anakinra) within 48 hours prior to randomization&#xD;
&#xD;
         21. Currently receiving therapeutic anticoagulation or anti platelet medication and unable&#xD;
             to stop the medication prior to randomization. Prophylactic anticoagulation therapy or&#xD;
             aspirin (≤ 100mg) are permitted.&#xD;
&#xD;
         22. Unable to ingest capsules or tablets at randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Volpone</last_name>
    <phone>206-351-7663</phone>
    <email>jvolpone@ctibiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simran Singh</last_name>
    <phone>206-384-9968</phone>
    <email>ssingh@ctibiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension St. Vincent's Riverside Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Agnes Healthcare</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital - Novi Campus</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Melanoma Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chilton Medical Center</name>
      <address>
        <city>Pompton Plains</city>
        <state>New Jersey</state>
        <zip>07444</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. John Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension St. Francis Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension All Saints</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

